Join +750K new investors every month who copy stock picks from billionaire's portfoliosSign Up Free

Ocular Therapeutix reshuffles leadership, aims for retina care leadership

EditorRachael Rajan
Published 22/02/2024, 15:46
© Reuters.
OCUL
-

BEDFORD, Mass. - Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on eye diseases, has announced significant changes to its board of directors and executive team.

The company appointed Pravin U. Dugel, MD as Executive Chairman, Jeffrey S. Heier, MD as Chief Scientific Officer, Peter K. Kaiser, MD as Medical Director, and Sanjay Nayak, MBBS, PhD as Chief Strategy Officer. Charles Warden transitioned from Chairman of the Board to Lead Independent Director.

The leadership expansion is part of Ocular's strategy to become a leading provider in retina care, especially for wet age-related macular degeneration (wet AMD (NASDAQ:AMD)), diabetic retinopathy, and other retinal conditions. The company believes these appointments can accelerate the development of its AXPAXLI™ Phase 3 wet AMD program.

Dr. Heier and Dr. Kaiser have resigned from their previous advisory roles to assume their new operational positions. Peter Jarrett, PhD, has also joined as Chief Technical Officer, while Rabia Gurses Ozden, MD, continues as Chief Medical Officer.

Antony Mattessich, CEO of Ocular Therapeutix, expressed confidence that the new 'Retina Dream Team' will advance the development of AXPAXLI™ and position the company at the forefront of retina care. He praised Dr. Dugel's track record in advancing novel products for retinal disease and his extensive network within the field. Mattessich also noted the valuable experience Drs. Heier, Kaiser, and Nayak bring to the company's clinical programs and strategic development.

The new appointments are expected to enhance Ocular's clinical trial outcomes, leveraging the team's expertise as principal investigators in pivotal trials for approved products for wet AMD and other ophthalmic indications.

Ocular Therapeutix is known for its proprietary bioresorbable hydrogel-based formulation technology, ELUTYX™, and its clinical portfolio includes the AXPAXLI™, currently in Phase 3 trials for wet AMD, and a Phase 1 trial for diabetic retinopathy.

The information in this article is based on a press release statement from Ocular Therapeutix, Inc.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.